Pharmaceuticals, Biotechnology and Life Sciences
ASCO data show more than 10% of patients on IMFINZI plus chemotherapy had not progressed and remained on treatment at…
Highly Selective and Potent Oral CDK7 Inhibitor Shows Robust Anti-Tumor Activity in Colorectal Cancer Models CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ:SYRS),…
Data presented at ASCO showed patients treated with a single, priming dose of tremelimumab plus IMFINZI achieved longest median survival…
61.9% of patients with HER2 mutant metastatic non-small cell lung cancer treated with ENHERTU achieved a tumor response Breakthrough Therapy…
– Data reinforce potential of FCR001 to induce long-lasting immune tolerance to donated organ – BOSTON–(BUSINESS WIRE)–Talaris Therapeutics, Inc., a…
– TUKYSA Combination Reduced Risk of Cancer Progression in the Brain or Death by Two-Thirds, Doubled Response Rate and Reduced…
– Pevonedistat Combination Demonstrates the Potential to Double Complete Remissions and Improve Outcomes in HR-MDS, With Safety Profile Similar to…
NEW YORK–(BUSINESS WIRE)–Aptorum Group Limited (NASDAQ:APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet…
– Oral Presentations of the Phase 2 OPTIC Interim Analysis at the American Society of Clinical Oncology (ASCO) and the…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the promotion…